deucravacitinib
Selected indexed studies
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. (J Am Acad Dermatol, 2023) [PMID:35820547]
- Deucravacitinib. (, 2012) [PMID:38471025]
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. (Arthritis Rheumatol, 2023) [PMID:36369798]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. (2023) pubmed
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. (2023) pubmed
- Deucravacitinib. (2012) pubmed
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. (2023) pubmed
- Deucravacitinib in the treatment of psoriasis. (2023) pubmed
- Deucravacitinib in moderate-to-severe psoriasis. (2022) pubmed
- Deucravacitinib: First Approval. (2022) pubmed
- Deucravacitinib for plaque psoriasis. (2024) pubmed
- Deucravacitinib. (2006) pubmed
- Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. (2025) pubmed